Paxman AB (publ) (STO:PAX)
46.75
-0.40 (-0.85%)
Jul 24, 2026, 5:15 PM CET
Paxman AB Revenue
Paxman AB had revenue of 90.97M SEK in the quarter ending March 31, 2026, with 30.67% growth. This brings the company's revenue in the last twelve months to 344.91M, up 26.76% year-over-year. In the year 2025, Paxman AB had annual revenue of 323.56M with 22.93% growth.
Revenue (ttm)
344.91M
Revenue Growth
+26.76%
P/S Ratio
3.15
Revenue / Employee
2.41M
Employees
143
Market Cap
1.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 323.56M | 60.36M | 22.93% |
| Dec 31, 2024 | 263.20M | 42.59M | 19.30% |
| Dec 31, 2023 | 220.61M | 63.86M | 40.74% |
| Dec 31, 2022 | 156.75M | 52.04M | 49.70% |
| Dec 31, 2021 | 104.71M | 19.23M | 22.50% |
| Dec 31, 2020 | 85.48M | -10.19M | -10.65% |
| Dec 31, 2019 | 95.67M | 27.11M | 39.54% |
| Dec 31, 2018 | 68.56M | 32.28M | 88.96% |
| Dec 31, 2017 | 36.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BICO Group AB | 1.49B |
| CellaVision AB | 739.15M |
| C-Rad AB | 444.40M |
| Mentice AB | 310.55M |
| Devyser Diagnostics AB | 250.30M |
| Bactiguard Holding AB | 206.94M |
| Sedana Medical AB | 195.46M |
| OssDsign AB | 172.55M |
Paxman AB News
- 2 months ago - Paxman AB Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Paxman AB Quarterly report: Q1 2026 - Filings
- 4 months ago - Paxman AB Transcript: DNB Carnegie Healthcare Seminar 2026 - Transcripts
- 5 months ago - Paxman AB Earnings Call Transcript: Q4 2025 - Transcripts
- 5 months ago - Paxman AB Quarterly report: Q4 2025 - Filings
- 5 months ago - Paxman AB Annual report: Q4 2025 - Filings
- 8 months ago - Paxman AB Transcript: DNB Carnegie Småbolagsdag - Transcripts
- 8 months ago - Paxman AB Transcript: CMD 2025 - Transcripts